Effect of Recombinant Human Granulocyte Colony- Stimulating Factor on CD11b in Septic Neonates

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators aimed to evaluate the effect of G-CSF administration in septic neonates on neutrophil production and CD11b expression.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Ain Shams University
• Treatments: Lenograstim; Sargramostim

Criteria

Inclusion Criteria:

• newborn infants with postnatal age < 28 day,

• minimum gestational age of 28 weeks and requiring intensive care with clinical signs consistent with the diagnosis of neonatal sepsis,

• with or without neutropenia

Exclusion Criteria:

• neonates with congenital malformation,

• major chromosomal abnormalities,

• prior use of cytokines or intravenous immunoglobulin, or decreased hemoglobin and/or hematocrit at or below the levels necessitate transfusion